Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
Status:
Completed
Trial end date:
2009-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to investigate whether or not oral maribavir is safe
and effective compared to oral ganciclovir for preventing CMV disease when administered for
up to 14 weeks in patients who have had a liver transplant.